Literature DB >> 3498532

Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.

V S Byers1, M V Pimm, I Z Pawluczyk, H M Lee, P J Scannon, R W Baldwin.   

Abstract

Immunotoxin constructed by conjugating ricin A chain to monoclonal antibody 791T/36 has a markedly altered biodistribution when compared to unconjugated antibody. This is principally manifest as hepatic uptake of immunotoxin which appears to be controlled by the ricin A chain (RTA) moiety. This was established by comparing the blood survival and organ distribution of immunotoxin with that of ricin A chain and free antibody using preparations in which either the RTA or antibody, alone or as components of the immunotoxin, was radiolabeled. Gel filtration chromatography of sera from immunotoxin treated animals demonstrated a preferential blood clearance of immunotoxin with high RTA-antibody ratio. Hepatic uptake is dependent upon Kupffer cell recognition of mannose-containing oligosaccharide structures on the RTA moiety of immunotoxin. Mannose-containing blocking agents given with immunotoxin were shown to prolong circulation time of the immunotoxin in blood including those species with higher RTA-monoclonal antibody ratios and reduce liver uptake. Effective blocking agents include ovalbumin, ovomucoid, and mannosyl-lysine (Man3Ly2). These studies demonstrate that agents specifically inhibiting hepatic uptake of immunotoxin significantly alter biodistribution and may improve their therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498532

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Targeted kill: from umbrellas to monoclonal antibodies.

Authors:  V S Byers; R W Baldwin
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

Review 2.  A role for gamma scintigraphy in cancer immunology and immunotherapy.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1992

Review 3.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

5.  Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Authors:  L G Durrant; V S Byers; P J Scannon; R Rodvien; K Grant; R A Robins; R A Marksman; R W Baldwin
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

6.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

Review 7.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

8.  Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.

Authors:  V S Byers; E B Austin; J A Clegg; G Denton; B Gunn; D Hooi; F Hudecz; M R Price; R W Baldwin
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

9.  Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts.

Authors:  M V Pimm; M A Paul; Y Ogumuyiwa; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.

Authors:  J A Calvete; D R Newell; C J Charlton; A F Wright
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.